Benjamin Hohl, CFO: Enliven Therapeutics ELVN Sell · Filed 25/03/31

Trade details

Type: Insider sale
Amount: $69,322.5
Shares · price: 3,250 sh · $21.33 a share
Held after: 23,000 sh
Stock: Enliven Therapeutics ELVN
Person: Benjamin HohlCFO
Trade date: 25/03/27
Filed: 25/03/31
Days to filing: 4 days

Sold 12.4% of holdings

Share of holding sold: 12.4%

Enliven Therapeutics trades, last 26 weeks

What else happened in Enliven Therapeutics around then

Filed or reported within 30 days of the trade day · 25/02/25~25/04/26

Benjamin Hohl's recent trades

Benjamin HohlCFO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$591.2K
12,036 sh
$591.2K
Filed 09/17
Traded 09/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$149.2K
3,401 sh
$149.2K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$59K
1,379 sh
$59K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Sell10b5-1 planEnliven Therapeutics
Sell10b5-1 plan
Enliven Therapeutics
ELVN
$55.4K
1,238 sh
$55.4K
Filed 06/22
Traded 06/17
Benjamin HohlCFO
Planned sale10b5-1 planEnliven Therapeutics
Planned sale10b5-1 plan
Enliven Therapeutics
ELVN
$768.2K
18,054 sh
$768.2K
Filed 06/17
Traded 06/17

Benjamin Hohl, CFO — sold $69.3K of Enliven Therapeutics ELVN · 12.4% of holdings · 10b5-1 plan | Whalegun